Harvard Bioscience Inc. (HBIO)'s InBreath Bioreactor Highlighted in Article in The Lancet Summarizing the World's First Synthetic Trachea Transplant
11/28/2011 11:20:43 AM
HOLLISTON, Mass., Nov. 28, 2011 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO - News), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, was highlighted in an article published in The Lancet, a leading peer-reviewed medical journal. The article described the world's first synthetic trachea transplant, conducted on June 9, 2011 at the Karolinska University Hospital in Sweden. The procedure involved a stem-cell-seeded bioartificial nanocomposite trachea that was grown in Harvard Bioscience's "InBreath" bioreactor that was produced in its regenerative medicine device business.
comments powered by